Senazodan is primarily explored for its potential therapeutic applications in the field of cardiovascular medicine. It functions as a phosphodiesterase III inhibitor, which means it helps in increasing the levels of cyclic AMP in cardiac and vascular smooth muscle cells. This action leads to enhanced myocardial contractility and vasodilation, making it a candidate for the treatment of heart failure. By improving heart function and reducing the workload on the heart, Senazodan can help alleviate symptoms associated with congestive heart failure, such as shortness of breath and fatigue. Additionally, its vasodilatory effects can contribute to lowering blood pressure, which is beneficial in managing hypertension. Research and clinical trials are ongoing to further understand its efficacy and safety profile in these applications.